Latest Breaking News On - Menarini asia pacific holdings - Page 1 : comparemela.com

Vaborem, a patented combination of meropenem and vaborbactam, is expected to address the rising prevalence of carbapenem-resistant Klebsiella pneumoniae (CRKP) infections in China The deal brings together Melinta's innovation, Menarini's cross-regional expertise in registration and marketing this asset, and SciClone's development and commercial presence in China Menarini will receive a total payment of up to 115 million, which includes milestone payments and tiered royalty on net sales, during the term SINGAPORE, Sept. 20, 2022 /PRNewswire/ A. Menarini Asia-Pacific Holdings Pte. Ltd., part of The Menarini Group, and SciClone Pharmaceuticals (Holdings) Limited have entered into an exclusive licensing agreement to develop and commercialize Vaborem (meropenem and vaborbactam) in the People's Republic of China (China). This initiative serves to expand options to address the public health threat of antimicrobial resistant infections, specifically carbapenem-resistant Enter

United statesChong zhaoChristine ann millerMaurizio luongoMenarini asia pacificSciclone pharmaceuticals holdings limitedSourcea menarini asia pacific holdings pteWorld health organizationChina antimicrobial surveillance networkSciclone pharmaceuticals holdingsEuropean unionMenarini groupSciclone pharmaceuticalsPrnewswirea menarini asia pacific holdings pteMelinta therapeuticsMenarini asia pacific holdings